Revolution Medicines Begins Treating Patients In RASolute 305, Global, Randomized Phase 3 Clinical Trial Evaluating Zoldonrasib In Combination With Standard Of Care Chemotherapy As First Line Treatment In Patients With Metastatic RAS G12D PDAC

뉴스 본문을 불러오고 있어요.

Revolution Medicines Begins Treating Patients In RASolute 305, Global, Randomized Phase 3 Clinical Trial Evaluating Zoldonrasib In Combination With Standard Of Care Chemotherapy As First Line Treatment In Patients With Metastatic RAS G12D PDAC | 웨이프 WAPE

Revolution Medicines Begins Treating Patients In RASolute 305, Global, Randomized Phase 3 Clinical Trial Evaluating Zoldonrasib In Combination With Standard Of Care Chemotherapy As First Line Treatment In Patients With Metastatic RAS G12D PDAC

기사 요약

관련 종목

댓글 —